217 related articles for article (PubMed ID: 32551907)
21. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT.
Schmidt S; Meuli RA; Achtari C; Prior JO
Clin Nucl Med; 2015 May; 40(5):371-7. PubMed ID: 25783507
[TBL] [Abstract][Full Text] [Related]
22. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls.
De Gaetano AM; Calcagni ML; Rufini V; Valenza V; Giordano A; Bonomo L
Abdom Imaging; 2009; 34(3):391-402. PubMed ID: 18446399
[TBL] [Abstract][Full Text] [Related]
23. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study).
Fischerova D; Pinto P; Burgetova A; Masek M; Slama J; Kocian R; Frühauf F; Zikan M; Dusek L; Dundr P; Cibula D
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):248-262. PubMed ID: 33871110
[TBL] [Abstract][Full Text] [Related]
24. Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers.
Tsoi TT; Chiu KWH; Chu MY; Ngan HYS; Lee EYP
J Ovarian Res; 2020 May; 13(1):61. PubMed ID: 32434520
[TBL] [Abstract][Full Text] [Related]
25. F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer.
Gallicchio R; Nardelli A; Venetucci A; Capacchione D; Pelagalli A; Sirignano C; Mainenti P; Pedicini P; Guglielmi G; Storto G
Eur J Radiol; 2017 Aug; 93():107-113. PubMed ID: 28668403
[TBL] [Abstract][Full Text] [Related]
26. Combining Diffusion-Weighted Imaging and T2-Weighted Imaging to Delineate Tumorous Tissue in Peritoneal Carcinomatosis: A Comparative Study with 18F-Fluoro-Deoxyglucose Positron Emission Tomography with Computed Tomography (FDG PET/CT).
Wu Q; Xu X
Med Sci Monit; 2022 Apr; 28():e934664. PubMed ID: 35370286
[TBL] [Abstract][Full Text] [Related]
27.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
28. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
29. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT.
Kim HW; Won KS; Zeon SK; Ahn BC; Gayed IW
Clin Nucl Med; 2013 Feb; 38(2):93-7. PubMed ID: 23334121
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of diffusion-weighted imaging and
Noij DP; Martens RM; Zwezerijnen B; Koopman T; de Bree R; Hoekstra OS; de Graaf P; Castelijns JA
Eur J Radiol; 2018 Oct; 107():20-25. PubMed ID: 30292267
[TBL] [Abstract][Full Text] [Related]
31. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI.
Klumpp BD; Schwenzer N; Aschoff P; Miller S; Kramer U; Claussen CD; Bruecher B; Koenigsrainer A; Pfannenberg C
Abdom Imaging; 2013 Feb; 38(1):64-71. PubMed ID: 22476333
[TBL] [Abstract][Full Text] [Related]
32. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
33. Performance of Multiparametric Functional Imaging to Assess Peritoneal Tumor Burden in Ovarian Cancer.
Mallet E; Angeles MA; Cabarrou B; Chardin D; Viau P; Frigenza M; Navarro AS; Ducassou A; Betrian S; Martínez-Gómez C; Tanguy Le Gac Y; Chantalat E; Motton S; Ferron G; Barranger E; Gabiache E; Martinez A
Clin Nucl Med; 2021 Oct; 46(10):797-806. PubMed ID: 34238796
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Sommariva A; Evangelista L; Pintacuda G; Cervino AR; Ramondo G; Rossi CR
Abdom Radiol (NY); 2018 May; 43(5):1094-1100. PubMed ID: 28770289
[TBL] [Abstract][Full Text] [Related]
35. The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL; Teixeira FR; Diniz TP; Faloppa CC; Mantoan H; da Costa AABA; Baiocchi G
J Gynecol Oncol; 2023 May; 34(3):e31. PubMed ID: 36731894
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal carcinomatosis: imaging with 64-MDCT and 3T MRI with diffusion-weighted imaging.
Iafrate F; Ciolina M; Sammartino P; Baldassari P; Rengo M; Lucchesi P; Sibio S; Accarpio F; Di Giorgio A; Laghi A
Abdom Imaging; 2012 Aug; 37(4):616-27. PubMed ID: 21972153
[TBL] [Abstract][Full Text] [Related]
37. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
[TBL] [Abstract][Full Text] [Related]
38. Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT.
Rakheja R; Makis W; Hickeson M
Abdom Imaging; 2012 Apr; 37(2):304-8. PubMed ID: 21394599
[TBL] [Abstract][Full Text] [Related]
39. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis.
Suzuki A; Kawano T; Takahashi N; Lee J; Nakagami Y; Miyagi E; Hirahara F; Togo S; Shimada H; Inoue T
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1413-20. PubMed ID: 15205922
[TBL] [Abstract][Full Text] [Related]
40. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
